<DOC>
	<DOCNO>NCT00711542</DOCNO>
	<brief_summary>Coronary flow reserve important measure integrity coronary microcirculation . Moreover , impaired coronary flow reserve predictor future cardiovascular event poor prognosis patient acute myocardial infarction . After acute myocardial infarction , coronary flow reserve remain significantly reduce . A previous randomize , double-blind Placebo-controlled trial ( REPAIR-AMI ) demonstrate complete normalization coronary flow reserve intracoronary application autologous bone marrow-derived progenitor cell ( effect placebo group ) patient ST segment elevation myocardial infarction . The current study plan extend finding patient Non-ST segment elevation myocardial infarction , since patient equally reduce outcome .</brief_summary>
	<brief_title>Effects Intracoronary Progenitor Cell Therapy Coronary Flow Reserve After Acute MI</brief_title>
	<detailed_description>Improvement neovascularization key mechanism functional improvement intracoronary application progenitor cell acute myocardial infarction . Since capillary density assess histological patient , measurement coronary flow reserve exact mean estimate capillary density assess coronary microvascular function . With help intracoronary Doppler Wire , coronary hemodynamics assess baseline , example , adenosin-induced maximal vasodilation . Calculation minimal vascular resistance index allow estimate cross-sectional area , reflect capillary density , , comparison time acute myocardial infarction , estimation improve neovascularization later timepoint . In order improve neovascularization , may associate improved left ventricular contractility , initiate current trial .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients acute coronary syndrome ( STdepression least 2 lead &gt; 0,1 mV ) , Twave inversion , without elevate myocardial biomarkers ( Troponin T oder I ) , together typical clinical presentation ) , treat follow : Acute percutaneous revascularization stent implantation within 48 hour symptom onset . Successful acute PCI ( residual stenosis &lt; 30 % , TIMI flow &gt; 2 ) . Hemodynamic stability Age 18 80 year Written inform consent Active contraception woman childbearing age Patients STEMI ( ST elevation 2 lead 0,2 mV lead V1 , V2 oder V3 0,1 mV lead ) Necessity additional PCI noninfarct vessel time study therapy ( multivessel PCI acute event possible ) Heart failure ( LVEF ≤ 30 % ) . Arteriovenous malformation aneurysm Active infection ( Creactive protein &gt; 10 mg/dl ) , fever , diarrhoea within last 4 week Chronic inflammatory disease HIV infection active hepatitis Neoplastic disease without documented complete remission within last 5 year Recent stroke within last 3 month Impaired kidney function ( creatinin &gt; 2,5 mg/dl ) time treatment Significant liver disease ( GOT &gt; 2x upper normal value spontaneous INR &gt; 1,5 . Hematopoetic disease ( anaemia Hb &lt; 8.5 mg/dl ; thrombocytopenia &lt; 100.000/µl ; splenomegaly Known allergy Clopidogrel , Heparin Abciximab History bleed disorder GI bleeding within last 3 month Major surgery trauma within last 2 month Uncontrolled hypertension Pregnancy Mental disability Previous progenitor cell therapy Participation different clinical trial within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>intracoronary progenitor cell therapy</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>coronary flow reserve</keyword>
	<keyword>randomize doubleblind Placebo-controlled trial</keyword>
</DOC>